A recombinant spike‐XBB.1.5 protein vaccine induces broad‐spectrum immune responses against XBB.1.5‐included Omicron variants of SARS‐CoV‐2
MedComm · 2023-06 · 4 (3)
DOI: 10.1002/mco2.263 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedComm, online erschienen am 26.04.2023. Verfasst von Cai He und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Aging Research and Cancer Drug Target State Key Laboratory of Biotherapy and Cancer Center National Clinical Research Center for Geriat…. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The XBB.1.5 subvariant has drawn great attention owing to its exceptionality in immune evasion and transmissibility. Therefore, it is essential to develop a universally protective coronavirus disease 2019 vaccine against various strains of Omicron, especially XBB.1.5. In this study, we evaluated and compared the immune responses induced by six different spike protein vaccines targeting the ancestral or various Omicron strains of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in mice. We found that spike‐wild‐type immunization induced high titers of neutralizing antibodies (NAbs) against ancestral SARS‐CoV‐2. However, its activity in neutralizing Omicron subvariants decreased sharply as the number of mutations in receptor‐binding domain (RBD) of these viruses increased. Spike‐BA.5, spike‐BF.7, and spike‐BQ.1.1 vaccines induced strong NAbs against BA.5, BF.7, BQ.1, and BQ.1.1 viruses but were poor in protecting against XBB and XBB.1.5, which have more RBD mutations. In sharp contrast, spike‐XBB.1.5 vaccination can activate strong and broadly protective immune responses against XBB.1.5 and other common subvariants of Omicron. By performing correlation analysis, we found that the NAbs titers were negatively correlated with the number of RBD mutations in the Omicron subvariants. Vaccines with more RBD mutations can effectively overcome the immune resistance caused by the accumulation of RBD mutations, making spike‐XBB.1.5 the most promising vaccine candidate against universal Omicron variants.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Aging Research and Cancer Drug Target State Key Laboratory of Biotherapy and Cancer Center National Clinical Research Center for Geriatrics West China Hospital Sichuan University Chengdu China.
ORCID-Profile: Cai He, Weiqi Hong, Xiawei Wei
Zitieren
APA
He, C., Alu, A., Lei, H., Yang, J., Hong, W., Song, X., Li, J., Yang, L., Wang, W., Shen, G., Lu, G., & Wei, X. (2023). A recombinant spike‐XBB.1.5 protein vaccine induces broad‐spectrum immune responses against XBB.1.5‐included Omicron variants of SARS‐CoV‐2. MedComm, 4(3). https://doi.org/10.1002/mco2.263
Vancouver
He C, Alu A, Lei H, Yang J, Hong W, Song X, et al. A recombinant spike‐XBB.1.5 protein vaccine induces broad‐spectrum immune responses against XBB.1.5‐included Omicron variants of SARS‐CoV‐2. MedComm. 2023;4(3). doi:10.1002/mco2.263
BibTeX
@article{He2023,
author = {He, Cai and Alu, Aqu and Lei, Hong and Yang, Jingyun and Hong, Weiqi and Song, Xiangrong and Li, Jiong and Yang, Li and Wang, Wei and Shen, Guobo and Lu, Guangwen and Wei, Xiawei},
title = {A recombinant spike‐XBB.1.5 protein vaccine induces broad‐spectrum immune responses against XBB.1.5‐included Omicron variants of SARS‐CoV‐2},
journal = {MedComm},
year = {2023},
volume = {4},
number = {3},
doi = {10.1002/mco2.263}
}
EUVIMED